Comparison of remimazolam and midazolam for preventing intraoperative nausea and vomiting during cesarean section under spinal anesthesia: a randomized controlled trial
Korean Journal of Anesthesiology · 2024
DOI: 10.4097/kja.24311 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Korean Journal of Anesthesiology, 2024. Verfasst von Kyuho Lee und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Pain Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Midazolam, Anesthesia, Spinal, Cesarean Section, Hypnotics and Sedatives. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hana Pharm Co., Ltd.
Abstract (Originalsprache)
Background
Preventing intraoperative nausea and vomiting (IONV) is crucial for maternal safety during cesarean section under spinal anesthesia. While midazolam is known to prevent IONV, we hypothesized that remimazolam would be superior due to its minimal hemodynamic effects. We compared the effects of the two drugs on IONV.
Methods
Parturients scheduled for cesarean section were randomly assigned to receive either midazolam or remimazolam. They received midazolam 2 mg or remimazolam 5 mg, with additional doses administered upon request. The primary outcome measure was the incidence of newly developed IONV during sedation. Other outcomes included overall IONV, rescue antiemetic use, shivering, hemodynamic variables, sedation scale scores, and satisfaction scores.
Results
Data from 80 participants were analyzed. Deeper sedation was induced in the remimazolam group (PGroup × Time < 0.001) despite comparable hemodynamic trends between the groups. The incidence of overall IONV was comparable between the two groups (27.5% in the midazolam group vs. 17.5% in the remimazolam group, absolute risk reduction [ARR]: 0.100, 95% CI [−0.082, 0.282], P = 0.284); however, newly developed IONV during sedation was significantly reduced in the remimazolam group (20.0% vs. 5.0%, ARR: 0.150, 95% CI [0.009, 0.291], P = 0.043). The need for rescue antiemetics was also lower in the remimazolam group (15.0% vs. 2.5%, ARR: 0.125, 95% CI [0.004, 0.246], P = 0.048).
Conclusion
Remimazolam significantly reduced the incidence and severity of newly developed IONV compared with midazolam, with minimal impact on hemodynamics, making it a useful sedative option for cesarean section.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Pain Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
- Department of Anesthesiology and Pain Medicine, MINT Hospital, Seoul, Korea.
Förderung
- Hana Pharm Co., Ltd
Zitieren
APA
Lee, K., Choi, S. H., Kim, S., Kim, H. D., Oh, H., & Kim, S. H. (2024). Comparison of remimazolam and midazolam for preventing intraoperative nausea and vomiting during cesarean section under spinal anesthesia: a randomized controlled trial. Korean Journal of Anesthesiology. https://doi.org/10.4097/kja.24311
Vancouver
Lee K, Choi SH, Kim S, Kim HD, Oh H, Kim SH. Comparison of remimazolam and midazolam for preventing intraoperative nausea and vomiting during cesarean section under spinal anesthesia: a randomized controlled trial. Korean Journal of Anesthesiology. 2024. doi:10.4097/kja.24311
BibTeX
@article{Lee2024,
author = {Lee, Kyuho and Choi, Seung Ho and Kim, Sangil and Kim, Hae Dong and Oh, Hyejin and Kim, Seung Hyun},
title = {Comparison of remimazolam and midazolam for preventing intraoperative nausea and vomiting during cesarean section under spinal anesthesia: a randomized controlled trial},
journal = {Korean Journal of Anesthesiology},
year = {2024},
doi = {10.4097/kja.24311}
}
EUVIMED